Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
ConSensus: Multi-Agent Collaboration for Multimodal Sensing
arXiv:2601.06453v1 Announce Type: new Abstract: Large language models (LLMs) are increasingly grounded in sensor data to perceive and reason about human physiology and the physical world. However, accurately interpreting heterogeneous multimodal sensor data remains a fundamental challenge. We show that a single monolithic LLM often fails to reason coherently across modalities, leading to incomplete interpretations and prior-knowledge bias. We introduce ConSensus, a training-free multi-agent col
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Large-Scale Study on the Development and Issues of Multi-Agent AI Systems
arXiv:2601.07136v1 Announce Type: cross Abstract: The rapid emergence of multi-agent AI systems (MAS), including LangChain, CrewAI, and AutoGen, has shaped how large language model (LLM) applications are developed and orchestrated. However, little is known about how these systems evolve and are maintained in practice. This paper presents the first large-scale empirical study of open-source MAS, analyzing over 42K unique commits and over 4.7K resolved issues across eight leading systems. Our ana
A Large-Scale Study on the Development and Issues of Multi-Agent AI Systems
-
cs.AI, q-bio.NC updates on arXiv.org
-
app.build: A Production Framework for Scaling Agentic Prompt-to-App Generation with Environment Scaffolding
arXiv:2509.03310v2 Announce Type: replace Abstract: We present app.build (https://github.com/neondatabase/appdotbuild-agent), an open-source framework that improves LLM-based application generation through systematic validation and structured environments. Our approach combines multi-layered validation pipelines, stack-specific orchestration, and model-agnostic architecture, implemented across three reference stacks. Through evaluation on 30 generation tasks, we demonstrate that comprehensive v
app.build: A Production Framework for Scaling Agentic Prompt-to-App Generation with Environment Scaffolding
-
Journal of Medical Internet Research
-
Key Information Influencing Patient Decision-Making About AI in Health Care: Survey Experiment Study
Background: Artificial Intelligence (AI)-enabled devices are increasingly used in healthcare. However, there has been limited research on patients’ informational preferences, including which elements of AI device labeling enhance patient understanding, trust, and acceptance. Clear and effective patient-facing communication is essential to address patient concerns and support informed decision-making regarding AI-enabled care. Objective: Using simulated AI device labels in a cardiovascular contex
Key Information Influencing Patient Decision-Making About AI in Health Care: Survey Experiment Study
-
InfoQ

-
FACTS Benchmark Suite Introduced to Evaluate Factual Accuracy of Large Language Models
A new industry benchmark aimed at systematically evaluating the factual accuracy of LLMs has been released with the launch of the FACTS Benchmark Suite. Developed by the FACTS team in collaboration with Kaggle, the suite expands earlier work on factual grounding and introduces a broader, multi-dimensional framework for measuring how reliably language models produce factually correct responses. By Robert Krzaczyński
FACTS Benchmark Suite Introduced to Evaluate Factual Accuracy of Large Language Models
A new industry benchmark aimed at systematically evaluating the factual accuracy of LLMs has been released with the launch of the FACTS Benchmark Suite. Developed by the FACTS team in collaboration with Kaggle, the suite expands earlier work on factual grounding and introduces a broader, multi-dimensional framework for measuring how reliably language models produce factually correct responses.
By Robert Krzaczyński-
Nature Medicine
-
Interpretable inflammation landscape of circulating immune cells
Nature Medicine, Published online: 12 January 2026; doi:10.1038/s41591-025-04126-3Including data from 1,047 patients across 19 inflammatory diseases, a new atlas presents a comprehensive model of inflammation in circulating immune cells.
Interpretable inflammation landscape of circulating immune cells
Nature Medicine, Published online: 12 January 2026; doi:10.1038/s41591-025-04126-3
Including data from 1,047 patients across 19 inflammatory diseases, a new atlas presents a comprehensive model of inflammation in circulating immune cells.-
cs.AI, q-bio.NC updates on arXiv.org
-
The Evaluation Gap in Medicine, AI and LLMs: Navigating Elusive Ground Truth & Uncertainty via a Probabilistic Paradigm
arXiv:2601.05500v1 Announce Type: new Abstract: Benchmarking the relative capabilities of AI systems, including Large Language Models (LLMs) and Vision Models, typically ignores the impact of uncertainty in the underlying ground truth answers from experts. This ambiguity is particularly consequential in medicine where uncertainty is pervasive. In this paper, we introduce a probabilistic paradigm to theoretically explain how high certainty in ground truth answers is almost always necessary for e
The Evaluation Gap in Medicine, AI and LLMs: Navigating Elusive Ground Truth & Uncertainty via a Probabilistic Paradigm
-
cs.AI, q-bio.NC updates on arXiv.org
-
Benchmarking LLM-based Agents for Single-cell Omics Analysis
arXiv:2508.13201v2 Announce Type: replace-cross Abstract: The surge in multimodal single-cell omics data exposes limitations in traditional, manually defined analysis workflows. AI agents offer a paradigm shift, enabling adaptive planning, executable code generation, traceable decisions, and real-time knowledge fusion. However, the lack of a comprehensive benchmark critically hinders progress. We introduce a novel benchmarking evaluation system to rigorously assess agent capabilities in single-
Benchmarking LLM-based Agents for Single-cell Omics Analysis
-
STAT

-
Opinion: The NIH has lost its scientific integrity. So we left
We are National Institutes of Health scientists and administrators with more than 50 years of collective civil service. Or, more accurately, we were NIH scientists and administrators.Read the rest…
Opinion: The NIH has lost its scientific integrity. So we left
We are National Institutes of Health scientists and administrators with more than 50 years of collective civil service.
Or, more accurately, we were NIH scientists and administrators.


© Adobe
-
MRD
-
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventiona
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventional diagnostic tools. Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, alongside detailed characterization of the PDAC mutational landscape, offer a promising non-invasive approach for MRD detection. Emerging evidence indicates that MRD status can serve as a sensitive prognostic biomarker, identify patients at high risk of relapse, and guide personalized perioperative therapy, including optimization of adjuvant treatment. This review summarizes current knowledge on the biology and detection of MRD in PDAC, its implications for perioperative risk stratification and treatment decision-making, and discusses future directions for integrating MRD assessment into clinical practice to enable more precise, individualized patient management.
PMID:41514607 | PMC:PMC12784771 | DOI:10.3390/cancers18010094
-
Nature Medicine
-
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-zAnalysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z
Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.-
Nature Medicine
-
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04171-yIn a randomized, double-blind, placebo-controlled trial comparing autologous mRNA-engineered BCMA-targeting CAR T cell therapy versus placebo in patients with generalized myasthenia gravis, a significantly higher percentage of patients exhibited a reduction in disease activity in the treatment arm than in the placebo arm.
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04171-y
In a randomized, double-blind, placebo-controlled trial comparing autologous mRNA-engineered BCMA-targeting CAR T cell therapy versus placebo in patients with generalized myasthenia gravis, a significantly higher percentage of patients exhibited a reduction in disease activity in the treatment arm than in the placebo arm.-
cs.AI, q-bio.NC updates on arXiv.org
-
Sci-Reasoning: A Dataset Decoding AI Innovation Patterns
arXiv:2601.04577v1 Announce Type: new Abstract: While AI innovation accelerates rapidly, the intellectual process behind breakthroughs -- how researchers identify gaps, synthesize prior work, and generate insights -- remains poorly understood. The lack of structured data on scientific reasoning hinders systematic analysis and development of AI research agents. We introduce Sci-Reasoning, the first dataset capturing the intellectual synthesis behind high-quality AI research. Using community-vali
Sci-Reasoning: A Dataset Decoding AI Innovation Patterns
-
cs.AI, q-bio.NC updates on arXiv.org
-
Self-MedRAG: a Self-Reflective Hybrid Retrieval-Augmented Generation Framework for Reliable Medical Question Answering
arXiv:2601.04531v1 Announce Type: cross Abstract: Large Language Models (LLMs) have demonstrated significant potential in medical Question Answering (QA), yet they remain prone to hallucinations and ungrounded reasoning, limiting their reliability in high-stakes clinical scenarios. While Retrieval-Augmented Generation (RAG) mitigates these issues by incorporating external knowledge, conventional single-shot retrieval often fails to resolve complex biomedical queries requiring multi-step inferen
Self-MedRAG: a Self-Reflective Hybrid Retrieval-Augmented Generation Framework for Reliable Medical Question Answering
-
cs.AI, q-bio.NC updates on arXiv.org
-
Atlas 2 -- Foundation models for clinical deployment
arXiv:2601.05148v1 Announce Type: cross Abstract: Pathology foundation models substantially advanced the possibilities in computational pathology -- yet tradeoffs in terms of performance, robustness, and computational requirements remained, which limited their clinical deployment. In this report, we present Atlas 2, Atlas 2-B, and Atlas 2-S, three pathology vision foundation models which bridge these shortcomings by showing state-of-the-art performance in prediction performance, robustness, and
Atlas 2 -- Foundation models for clinical deployment
-
cs.AI, q-bio.NC updates on arXiv.org
-
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
arXiv:2512.00949v2 Announce Type: replace-cross Abstract: For patients undergoing systemic cancer therapy, the time between clinic visits is full of uncertainties and risks of unmonitored side effects. To bridge this gap in care, we developed and prospectively trialed a multi-modal AI framework for remote patient monitoring (RPM). This system integrates multi-modal data from the HALO-X platform, such as demographics, wearable sensors, daily surveys, and clinical events. Our observational trial
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
-
Journal of Medical Internet Research
-
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
Background: Structured medication reviews (SMRs) are an essential component of medication optimization, especially for patients with multimorbidity and polypharmacy. However, the process remains challenging due to the complexities of patient data, time constraints, and the need for coordination among health care professionals (HCPs). This study explores HCPs’ perspectives on the integration of artificial intelligence (AI)–assisted tools to enhance the SMR process, with a focus on the potential b
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
-
Journal of Medical Internet Research
-
Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
Background: The rapid growth of social media as an information channel has enabled the swift spread of inaccurate or false health information, significantly impacting public health. This widespread dissemination of misinformation has caused confusion, eroded trust in health authorities, led to noncompliance with health guidelines, and encouraged risky health behaviors. Understanding the dynamics of misinformation on social media is essential for devising effective public health communication str
Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
-
npj Digital Medicine
-
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
npj Digital Medicine, Published online: 07 January 2026; doi:10.1038/s41746-025-02324-4An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
npj Digital Medicine, Published online: 07 January 2026; doi:10.1038/s41746-025-02324-4
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models-
(Multiomics OR Omics) AND (Pancreatic)
-
Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine
J Transl Med. 2026 Jan 6. doi: 10.1186/s12967-025-07596-8. Online ahead of print.ABSTRACTINTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of < 13%. Standard treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel yield modest response rates, underscoring the urgent need for precision oncology approaches. Patient-derived organoids (PDOs) preserve the genomic, phenotypic, and histopathological features of the source tum
Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine
J Transl Med. 2026 Jan 6. doi: 10.1186/s12967-025-07596-8. Online ahead of print.
ABSTRACT
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of < 13%. Standard treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel yield modest response rates, underscoring the urgent need for precision oncology approaches. Patient-derived organoids (PDOs) preserve the genomic, phenotypic, and histopathological features of the source tumor and offer a promising platform for drug screening, biomarker development, and personalized therapy. However, a systematic evaluation of their translational capacities is lacking.
METHODS: A systematic review was conducted according to the PRISMA 2020 guidelines (PROSPERO registration pending) using PubMed, EMBASE, and Cochrane CENTRAL (December 10, 2024) to identify English-language PDAC PDO studies that incorporated therapeutic testing. Ninety-five studies met the inclusion criteria. Data extraction captured >75 variables per study, including spanning culture methodology, therapeutic profiling, biomarker integration, and clinical correlation. A 13-domain weighted Translatability Scoring Framework adapted from Wehling et al. assessed predictive validity, biomarker strength, pharmacogenetics, and clinical trial alignment. Scores ranged from 0 to 5 and were categorized as good (>4.0), moderate (3.0-4.0), or low (<3.0) translational potential.
RESULTS: Of the 95 studies, 70.5% have been published since 2021, reflecting the rapid growth in this field. The mean PDO generation success rate was 89.7%, with the primary tumor tissue being the predominant source (48.4%). Only 24.8% were directly linked to clinical trials and 5.3% incorporated multi-omic profiling. The median translatability score was 3.13 (range, 1.72-4.59): 45.3% of the studies had low translatability, 50.5% moderate, and only 4.2% had good translational potential. High-scoring studies consistently combine multi-omic biomarker platforms, in vivo validation, clinical outcome correlation, and prospective trial integration. Conversely, the weakest domains were pharmacogenetics, endpoint strategies, and biomarker validation, limiting their overall clinical relevance.
CONCLUSIONS: PDOs have demonstrated strong feasibility and in vitro clinical correlation in PDAC; however, their clinical translation remains constrained by limited multi-omic integration, absence of pharmacogenomic modeling, and sparse clinical trial embedding. Standardization of protocols, adoption of harmonized and clinically relevant endpoints, and systematic incorporation of biomarker-driven co-clinical trial frameworks are urgently needed to transition PDOs from promising experimental surrogates to validating precision oncology tools capable of informing therapeutic decision-making in PDAC.
PMID:41495743 | DOI:10.1186/s12967-025-07596-8